brexanolone — NDA/BLA submission
in 2026
We expect to report data from this Phase 3 trial in April 2026, and data from this trial are expected to support a 505(b)(2) NDA submission for LPCN 1154 in 2026.Source filing
LPCN biotech catalysts & pipeline
LIPOCINE INC · Data as of 2026-10-25
Upcoming catalysts
TLANDO® (testosterone undecanoate) — Regulatory decision
2027
The deferred revenue is expected to be recognized as revenue within 60 days of SPC's receipt of marketing authorization for TLANDO in South Korea (the "SPC Territory"), which is expected to occur in 2027.Source filing